

Heinrike Schmeling

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1505764/publications.pdf>

Version: 2024-02-01

34
papers

1,017
citations

567281

15
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

1421
citing authors

#	ARTICLE	IF	CITATIONS
1	The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1854-1860.	0.9	192
2	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	5.8	105
3	Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. <i>Lancet, The</i> , 2021, 398, 1984-1996.	13.7	79
4	The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1092-1098.	0.9	72
5	Efficacy and Safety of Adalimumab as the First and Second Biologic Agent in Juvenile Idiopathic Arthritis: The German Biologics JIA Registry. <i>Arthritis and Rheumatology</i> , 2014, 66, 2580-2589.	5.6	69
6	Development of System-level Performance Measures for Evaluation of Models of Care for Inflammatory Arthritis in Canada. <i>Journal of Rheumatology</i> , 2016, 43, 530-540.	2.0	63
7	Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. <i>Rheumatology</i> , 2011, 50, 885-893.	1.9	61
8	Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. <i>Arthritis Care and Research</i> , 2018, 70, 134-144.	3.4	50
9	Growth and weight gain in children with juvenile idiopathic arthritis: results from the ReACCh-Out cohort. <i>Pediatric Rheumatology</i> , 2017, 15, 68.	2.1	39
10	Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis. <i>Frontiers in Immunology</i> , 2019, 10, 745.	4.8	36
11	Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls. <i>Journal of Rheumatology</i> , 2015, 42, 2419-2426.	2.0	34
12	Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. <i>Pain</i> , 2018, 159, 57-66.	4.2	29
13	The <i>CanCope</i> pain self-management application for adolescents with juvenile idiopathic arthritis: a pilot randomized controlled trial. <i>Rheumatology</i> , 2021, 60, 196-206.	1.9	26
14	Management of Juvenile Idiopathic Arthritis 2015: A Position Statement from the Pediatric Committee of the Canadian Rheumatology Association. <i>Journal of Rheumatology</i> , 2016, 43, 1773-1776.	2.0	23
15	Pharmacogenetics: can genes determine treatment efficacy and safety in JIA?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 682-690.	8.0	17
16	Risk factors associated with <i>Pneumocystis jirovecii</i> pneumonia in juvenile myositis in North America. <i>Rheumatology</i> , 2021, 60, 829-836.	1.9	15
17	Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2021, 60, 4495-4507.	1.9	15
18	A new Canadian inception cohort for juvenile idiopathic arthritis: The Canadian Alliance of Pediatric Rheumatology Investigators Registry. <i>Rheumatology</i> , 2020, 59, 2796-2805.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Patient-Reported Barriers at School for Children with Juvenile Idiopathic Arthritis. <i>ACR Open Rheumatology</i> , 2019, 1, 182-187.	2.1	11
20	Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2020, 18, 22.	2.1	9
21	Association with HLA-DR ¹ position 37 distinguishes juvenile dermatomyositis from adult-onset myositis. <i>Human Molecular Genetics</i> , 2022, 31, 2471-2481.	2.9	9
22	A Canadian evaluation framework for quality improvement in childhood arthritis: key performance indicators of the process of care. <i>Arthritis Research and Therapy</i> , 2020, 22, 53.	3.5	8
23	Prevalence and titres of antinuclear antibodies in juvenile idiopathic arthritis: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2022, 21, 103086.	5.8	8
24	Testing population-based performance measures identifies gaps in juvenile idiopathic arthritis (JIA) care. <i>BMC Health Services Research</i> , 2019, 19, 572.	2.2	7
25	Impact of the COVID-19 pandemic on juvenile idiopathic arthritis presentation and research recruitment: results from the CAPRI registry. <i>Rheumatology</i> , 2022, 61, S1157-S1162.	1.9	6
26	A39: Efficacy and Safety of Methotrexate in Oligoarticular Persistent Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S59-S59.	5.6	5
27	A11: Assessment of Radiographic Progression in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Tocilizumab: 2-Year Data From CHERISH. <i>Arthritis and Rheumatology</i> , 2014, 66, S17-S18.	5.6	4
28	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1264-1274.	3.4	4
29	A38: Twelve Years' Experience with Etanercept in the Treatment of Juvenile Idiopathic Arthritis: How It Has Changed Practice-The German Biologics JIA Registry (BiKeR). <i>Arthritis and Rheumatology</i> , 2014, 66, S58-S58.	5.6	3
30	Purpura, petechiae, and bullae as first signs of juvenile granulomatosis with polyangiitis. <i>European Journal of Pediatrics</i> , 2014, 173, 1685-1689.	2.7	2
31	Parent-Reported Medication Side Effects and Their Impact on Health-Related Quality of Life in Children With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1567-1574.	3.4	2
32	Acceptability of an Adolescent Self-Management Program for Juvenile Idiopathic Arthritis. <i>ACR Open Rheumatology</i> , 2021, , .	2.1	2
33	170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
34	THU0516...LONG-TERM SAFETY OF SUBCUTANEOUS TOCILIZUMAB ADMINISTRATION IN SYSTEMIC AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. , 2019, , .		0